Cingulate Inc. Announces Financial Results for Q2 2025 and Shares Recent Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Source: Globenewswire
New Drug Application Submission: Cingulate Inc. has submitted a New Drug Application (NDA) to the FDA for its lead product, CTx-1301, an extended-release tablet formulation aimed at improving ADHD treatment.
FDA Decision Timeline: The company anticipates an FDA decision on NDA acceptance by Q4 2025, with a potential PDUFA date in mid-2026.
Financial Overview: As of June 30, 2025, Cingulate reported approximately $8.9 million in cash, a decrease from previous quarters, and plans to raise an additional $1.5 million for commercialization efforts.
Research and Development Costs: R&D expenses increased by 43.6% year-over-year due to costs associated with the NDA submission, while the net loss for the quarter was reported at $4.8 million.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
